 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 849188
Online Users : 1643
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/13538
|
| Title: | Arginine signaling and cancer metabolism |
| Authors: | Chen, CL;Hsu, SC;Ann, DK;Yen, Y;Kung, HJ |
| Contributors: | Institute of Molecular and Genomic Medicine;Institute of Cellular and Systems Medicine |
| Abstract: | Simple Summary In this review, we describe arginine's role as a signaling metabolite, epigenetic regulator and mitochondrial modulator in cancer cells, and summarize recent progress in the application of arginine deprivation as a cancer therapy. Arginine is an amino acid critically involved in multiple cellular processes including the syntheses of nitric oxide and polyamines, and is a direct activator of mTOR, a nutrient-sensing kinase strongly implicated in carcinogenesis. Yet, it is also considered as a non- or semi-essential amino acid, due to normal cells' intrinsic ability to synthesize arginine from citrulline and aspartate via ASS1 (argininosuccinate synthase 1) and ASL (argininosuccinate lyase). As such, arginine can be used as a dietary supplement and its depletion as a therapeutic strategy. Strikingly, in over 70% of tumors, ASS1 transcription is suppressed, rendering the cells addicted to external arginine, forming the basis of arginine-deprivation therapy. In this review, we will discuss arginine as a signaling metabolite, arginine's role in cancer metabolism, arginine as an epigenetic regulator, arginine as an immunomodulator, and arginine as a therapeutic target. We will also provide a comprehensive summary of ADI (arginine deiminase)-based arginine-deprivation preclinical studies and an update of clinical trials for ADI and arginase. The different cell killing mechanisms associated with various cancer types will also be described. |
| Date: | 2021-07-15 |
| Relation: | Cancers. 2021 Jul 15;13(14):Article number 3541. |
| Link to: | http://dx.doi.org/10.3390/cancers13143541 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2072-6694&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000676330700001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85110488935 |
| Appears in Collections: | [龔行健] 期刊論文
[其他] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI000676330700001.pdf | | 3514Kb | Adobe PDF | 809 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
